-
公开(公告)号：US20230159588A1
公开(公告)日：2023-05-25
申请号：US18094167
申请日：2023-01-06
发明人： SACHIKO YAMASHITA , TETSURO HIKICHI
摘要： The present invention provides CDCA1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
-
公开(公告)号：US10676508B2
公开(公告)日：2020-06-09
申请号：US15751406
申请日：2016-08-10
发明人： Sachiko Yamashita , Tetsuro Hikichi
IPC分类号： C07K7/00 , C07K7/06 , A61K39/00 , C12N5/10 , C12N15/09 , A61K31/7088 , C07K7/08 , A61P35/00 , C07K16/18 , C12N5/0783
摘要： The present invention provides DEPDC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
-
公开(公告)号：US20200174002A1
公开(公告)日：2020-06-04
申请号：US16336846
申请日：2017-10-04
发明人： YOSUKE HARADA , TATSUKI YOKOSEKI , YUSUKE NAKAMURA
IPC分类号： G01N33/574 , C07K16/28
摘要： The present invention relates to monoclonal antibodies against FZD10. Furthermore, the present invention provides methods for diagnosing FZD10-related diseases using such an antibody, methods for detecting a FZD10 protein, methods for determining drug efficacy after treatment with FZD10 inhibitors, and methods of screening for subjects in whom treatment with FZD10 inhibitors is highly effective, and provides diagnostic reagents containing such an antibody.
-
公开(公告)号：US20200093849A1
公开(公告)日：2020-03-26
申请号：US16708134
申请日：2019-12-09
IPC分类号： A61K31/7088 , A61K38/00 , A61K39/00 , A61K48/00 , C12N15/09 , C07K7/06 , C07K7/08 , C12Q1/02 , G01N33/15 , G01N33/50 , C07K16/18 , C12N5/10 , C07K14/705
摘要： The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
-
公开(公告)号：US10508109B2
公开(公告)日：2019-12-17
申请号：US15763389
申请日：2016-09-12
发明人： Yo Matsuo , Shoji Hisada , Yusuke Nakamura , Anjan Chakrabarti , Manish Rawat , Sanjay Rai , Arvapalli Venkata Satyanarayana , Zhiyong Duan , Arindam Talukdar , Srinivas Ravula , Helene Decornez
IPC分类号： C07D471/04 , C07D451/00 , C07D487/04 , C07D519/00 , C07F9/6561 , A61P35/00
摘要： The present invention directs to a compound represented by formula (I).
-
公开(公告)号：US20180346512A1
公开(公告)日：2018-12-06
申请号：US15762436
申请日：2016-10-06
发明人： Sachiko YAMASHITA , Tetsuro Hikichi
CPC分类号： A61K35/12 , A61K35/17 , A61K38/00 , A61K48/00 , C07K14/4705 , C07K16/32 , C12N5/10 , G01N33/505
摘要： The present invention provides FOXM1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
-
公开(公告)号：US09975935B2
公开(公告)日：2018-05-22
申请号：US15228785
申请日：2016-08-04
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe , Yusuke Nakamura , Yoichi Furukawa
CPC分类号： C07K14/4748 , A61K39/00 , A61K39/0011 , A61K39/39 , A61K2039/53 , A61K2039/572 , C12N9/88 , C12Y402/99018 , Y02A50/396
摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.
-
公开(公告)号：US09896492B2
公开(公告)日：2018-02-20
申请号：US15197278
申请日：2016-06-29
摘要： Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.
-
公开(公告)号：US09849166B2
公开(公告)日：2017-12-26
申请号：US15203103
申请日：2016-07-06
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama
IPC分类号： A61K38/00 , A61K39/00 , C07K16/18 , C07K7/06 , G01N33/574 , C07K14/47 , G01N33/50 , C12N9/12 , C07K16/40
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/0005 , A61K2039/5154 , A61K2039/572 , C07K7/06 , C07K14/4748 , C07K16/18 , C07K16/40 , C07K2317/34 , C12N9/12 , C12N9/1205 , C12Y207/12002 , G01N33/505 , G01N33/574
摘要： The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.
-
公开(公告)号：US20170362287A1
公开(公告)日：2017-12-21
申请号：US15534311
申请日：2015-12-04
发明人： YASUHARU NISHIMURA , YUSUKE TOMITA , RYUJI OSAWA
IPC分类号： C07K14/47 , G01N33/574 , C12N15/09 , A61K31/7088 , G01N33/68 , C07K7/06 , C12Q1/68 , C07K16/18 , A61K48/00
CPC分类号： C07K14/4725 , A61K31/7088 , A61K39/0011 , A61K48/00 , C07K7/06 , C07K14/47 , C07K16/18 , C12N15/09 , C12N2510/00 , C12Q1/68 , G01N33/574 , G01N33/57492 , G01N33/68
摘要： Isolated GPC3-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce GPC3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, hepatocellular carcinoma and melanoma.
-
-
-
-
-
-
-
-
-
搜索结果
320 条记录 (耗时 0.049 秒)
